Federico Pozzo

Aviano, Italy

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 41 publications

Dissecting diffuse large B-cell lymphoma heterogeneity: New insights from a state-specific molecular characterisation.

Dissecting diffuse large B-cell lymphoma heterogeneity: New insights from a state-specific molecular characterisation.

Journal: Clinical and translational medicine
Published: March 24, 2026

How many NOTCHes (activation pathways) are there in CLL?

How many NOTCHes (activation pathways) are there in CLL?

Journal: Blood
Published: October 16, 2025

Evaluation of Constitutive or Induced Activation State of the VLA-4 Integrin in Human and Murine Samples.

Evaluation of Constitutive or Induced Activation State of the VLA-4 Integrin in Human and Murine Samples.

Journal: Methods in molecular biology (Clifton, N.J.)
Published: March 03, 2025

Measurement of Immunoglobulin Intraclonal diversification refines the clinical impact of IGHV mutational status in chronic lymphocytic leukemia.

Measurement of Immunoglobulin Intraclonal diversification refines the clinical impact of IGHV mutational status in chronic lymphocytic leukemia.

Journal: Leukemia
Published: February 13, 2025

CD49d governs immune synapse formation through actin rearrangements and synchronizes BCR signaling in CLL.

CD49d governs immune synapse formation through actin rearrangements and synchronizes BCR signaling in CLL.

Journal: Blood
Published: November 30, 2024

Expression of HERV-K and embryonic genes in chronic lymphocytic leukemia and their association with therapy regimens.

Expression of HERV-K and embryonic genes in chronic lymphocytic leukemia and their association with therapy regimens.

Journal: Blood advances
Published: July 09, 2024

CD49d expression is included in a revised 4-factor model predicting outcome in patients with chronic lymphocytic leukemia treated with ibrutinib: A multicenter real-world experience.

CD49d expression is included in a revised 4-factor model predicting outcome in patients with chronic lymphocytic leukemia treated with ibrutinib: A multicenter real-world experience.

Journal: HemaSphere
Published: April 26, 2024

The VLA-4 integrin is constitutively active in circulating chronic lymphocytic leukemia cells via BCR autonomous signaling: a novel anchor-independent mechanism exploiting soluble blood-borne ligands.

The VLA-4 integrin is constitutively active in circulating chronic lymphocytic leukemia cells via BCR autonomous signaling: a novel anchor-independent mechanism exploiting soluble blood-borne ligands.

Journal: Leukemia
Published: March 04, 2024

Early reappearance of intraclonal proliferative subpopulations in ibrutinib-resistant chronic lymphocytic leukemia.

Early reappearance of intraclonal proliferative subpopulations in ibrutinib-resistant chronic lymphocytic leukemia.

Journal: Leukemia
Published: January 12, 2024

NFKBIE mutations are selected by the tumor microenvironment and contribute to immune escape in chronic lymphocytic leukemia.

NFKBIE mutations are selected by the tumor microenvironment and contribute to immune escape in chronic lymphocytic leukemia.

Journal: Leukemia
Published: November 09, 2023

TP53 Mutations and Clinical Outcome in Chronic Lymphocytic Leukemia: Is a Threshold Still Needed?

TP53 Mutations and Clinical Outcome in Chronic Lymphocytic Leukemia: Is a Threshold Still Needed?

Journal: HemaSphere
Published: April 10, 2023

Persistence of monoclonal B-cell expansion and intraclonal diversification despite virus eradication in patients affected by hepatitis C virus-associated lymphoproliferative disorders.

Persistence of monoclonal B-cell expansion and intraclonal diversification despite virus eradication in patients affected by hepatitis C virus-associated lymphoproliferative disorders.

Journal: British journal of haematology
Published: April 04, 2023
Showing 1-12 of 41

Last Updated: 09/26/2026